We are proud to announce our new R&D project entitled ‘Pilot Study on Possible Uses of the Patient-Derived Breast Cancer Organoid Model in Personalized Medicine Applications’, supported by the TÜBİTAK TEYDEB 1507 program. As ORGANO-ID, we would like to thank TÜBİTAK for supporting us in the validation of the PDCO test platform that we plan to implement in the treatment decision of breast cancer patients.
27 January 2023
Our company gained useful knowledge about strategic management during the trainings it received as part of the Dokuz Eylül Health Industry Export and International Competitiveness Development Project. Furthermore, ORGANO-ID expanded its professional network.
5-6 December 2022
Izmir Beyond Hotel
Prof. Dr. Esra Erdal, at the TRANSPLANTATION’22 Congress organized by the Turkish Organ Transplantation Organizations Coordination Association, mentioned that organoids, the technology currently used and developed by our company, can be used as an alternative to organ transplantation.
13-15 October 2022
Limak Cyprus Deluxe Hotel, Kıbrıs, Turkiye
Clinician collagues were very interested to the ORGANO-ID PDCOs to choose better treatment option for their patients.
28 September – 01 October 2022
Istanbul Congress Center, Turkiye
ORGANO-ID has successfully presented high-tech solutions for personalized cancer treatment and Pre-clinical Disease Modeling at TEKNOFEST in Samsun. TEKNOFEST Aerospace and Technology Festival is organized with the partnership of Turkey’s most important institutions and organizations whose main goals are realizing the National Technology Initiative and transforming Turkey into a technology developing society.
30th August – 4th September
Samsun Carsamba Airport, Turkiye
ORGANO-ID researchers presented a pilot study representing the efficiency of the patient derived cancer organoid model for personalized drug response prediction and discuss the data with the colleagues having expertise in the field.
9-12 June 2022
Acıbadem University, Istanbul, Turkiye